Relay Therapeutics Inc Forecast, price target & analysts
Relay Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Relay Therapeutics Inc Classifications & Recommendation:
Relay Therapeutics Inc Price Target
| Target Price | $20.91 |
| Price | $3.25 |
| Potential |
543.36%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Relay Therapeutics Inc 2026 .
The average Relay Therapeutics Inc target price is $20.91.
This is
543.36%
register free of charge
$30.00
823.08%
register free of charge
$16.00
392.31%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend Relay Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Relay Therapeutics Inc stock has an average upside potential 2026 of
543.36%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.01 | 3.52 |
| 60.82% | 64.87% | |
| EBITDA Margin | -3,798.30% | -11,414.07% |
| 159.38% | 200.50% | |
| Net Margin | -3,955.18% | -11,863.87% |
| 115.91% | 199.96% |
12 Analysts have issued a sales forecast Relay Therapeutics Inc 2025 . The average Relay Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Relay Therapeutics Inc EBITDA forecast 2025. The average Relay Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Relay Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Relay Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.36 | -2.49 |
| 15.41% | 5.51% | |
| P/E | negative | |
| EV/Sales | negative |
6 Analysts have issued a Relay Therapeutics Inc forecast for earnings per share. The average Relay Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Relay Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Relay Therapeutics Inc...
Current Relay Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Stifel | Locked ➜ Locked | Locked | Feb 27 2025 |
| Goldman Sachs | Locked ➜ Locked | Locked | Feb 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 14 2025 |
| JMP Securities | Locked ➜ Locked | Locked | Dec 12 2024 |
| Leerink Partners | Locked ➜ Locked | Locked | Dec 04 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 04 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 08 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Stifel: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 14 2025 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Dec 12 2024 |
|
Locked
Leerink Partners: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 08 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
